Other languages Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
6.01 ^USD	-5.50%		-6.24%	-56.89%

May. 08	Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102	May. 07
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 02
Top Midday Decliners	Apr. 02
Looming Factory Orders, Job Openings Data Prompt Lower Premarket Action for US Equity Futures	Apr. 02
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	Apr. 02
Sector Update: Health Care	Apr. 02
Verve Therapeutics Pauses Heart-1 Trial After Serious Adverse Events; Shares Fall Pre-Bell	Apr. 02
Top Premarket Decliners	Apr. 02
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels	Apr. 02
Verve Therapeutics, Inc. Announces Updates on its PCSK9 Program	Apr. 02
Verve Therapeutics Q4 Net Loss Widens, Collaboration Revenue Rises; Beats Estimates; Shares Rise	Feb. 27
Verve Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Verve Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27
Google Ventures adds partner to back AI, open source startups	Dec. 13
Sector Update: Health Care Stocks Advance Premarket Wednesday	Nov. 29
Rate Outlooks Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday	Nov. 29
Verve Therapeutics Prices $148 Million Common Stock Offering, Concurrent Private Placement; Shares Slump Pre-Bell	Nov. 29
Verve Therapeutics Prices Offering of Common Shares, Concurrent Private Placement for Proceeds of $148 Million	Nov. 29
Verve Therapeutics Proposes Common Stock Public Offering, Concurrent Private Placement -- Shares Slump After Hours	Nov. 28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Other languages

Filters